GSK Consumer Healthcare Pakistan Limited has lifted the event of force majeure declared on October 21, 2022, and resumed the full-capacity manufacturing of Panadol
GlaxoSmithKline – GSK Consumer Healthcare Pakistan Limited has lifted the event of force majeure declared on October 21, 2022, and resumed the full-capacity manufacturing of Panadol Tablets, Panadol Extra Tablets, and Children’s Panadol Liquid Range once an agreement was reached with the key federal government representatives, the company filing on PSX.
“We appreciate the efforts of the Federal Government to revise the prices of Panadol Tablets, Panadol Extra Tablets, and Children’s Panadol Liquid Range, which will help the Company to continue to produce everyday healthcare products without gross losses,” the notice read.
“We are specifically grateful to the Prime Minister, Finance Minister, SAPM for Finance, Health Minister, Health Secretary, CEO DRAP, and all other stakeholders in this regard,” it added.
The GSK Consumer Healthcare Pakistan further stated that though the price revisions granted do not fully mirror the sharp increase in the raw material prices of Paracetamol, the company has resumed production in the larger interest of consumers and patients in Pakistan.
The company is looking forward to further discussions and engagement with the Federal Government, in due course, to discuss our long-term strategy to provide better everyday health to humanity, and based on trusted science.
To recall, the Economic Coordination Committee (ECC) of the Cabinet on Oct, 28 approved to increase the price of Paracetamol products.
Originally published at M Link News